The Center for Biosimilars recaps the top 5 stories in biosimilars news for the week of August 14, 2017.
Transcript:
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of August 14.
Number 5: Biocon has withdrawn its filings for 2 biosimilars in Europe ahead of a re-inspection of its Bangalore manufacturing facility. The move sparked new questions as to whether the company’s trastuzumab will be cleared by the FDA next month.
Number 4: Dr Marcus Snow, of the University of Nebraska Medical Center, joined The Center for Biosimilars® to discuss the use of biosimilar treatments in children.
Number 3: With drug price reform efforts apparently stalled at the federal level, states are leading the fight against rising drug costs.
Number 2: A recent budget impact analysis shows that discounts for biosimilar infliximab may need to be deeper than previously believed in order to encourage uptake.
And Number 1: Rebates provided to PBMs by reference product sponsors may pose a threat to biosimilar uptake, and could force patients to pay high out-of-pocket costs.
Finally, last week, our newsletter asked you to share your thoughts on switching studies, and whether such studies should use a US-licensed reference product, an EU-licensed product, or a product approved by any global healthcare agency. To view results of the poll, follow The Center for Biosimilars® on LinkedIn.
To read these articles and more, visit centerforbiosimilars.com.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed
July 15th 2024Sarfaraz K. Niazi, PhD, discusses the challenges with pharmacy benefit managers (PBMs) that plague the biosimilar industry and new legislation that attempts to reform their practices and encourage biosimilar adoption.